- Home
- MOLN vs HUMA Comparison
MOLN vs HUMA Comparison
Compare MOLN & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MOLN | HUMA |
|---|---|---|
| Founded | 2004 | 2004 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.5M | 165.7M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MOLN | HUMA |
|---|---|---|
| Price | $3.67 | $0.36 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $10.36 | $1.63 |
| AVG Volume (30 Days) | 2.1K | ★ 4.4M |
| Earning Date | 10-29-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,038,000.00 |
| Revenue This Year | N/A | $72.32 |
| Revenue Next Year | $450.00 | $518.79 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.53 | $0.39 |
| 52 Week High | $5.36 | $1.90 |
Technical Indicators
Market Signals| Indicator | MOLN | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 39.09 | 19.61 |
| Support Level | N/A | N/A |
| Resistance Level | $4.39 | $0.75 |
| Average True Range (ATR) | 0.17 | 0.03 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 11.76 | 3.53 |
Price Performance
Historical ComparisonAbout MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
About HUMA Humacyte Inc.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.